Fate Therapeutics

Fate Therapeutics has reported promising early clinical data from its Phase I trials. For example:

• FT819, an off-the-shelf iPSC-derived CAR T-cell therapy targeting CD19 for moderate-to-severe SLE, received FDA Regenerative Medicine Advanced Therapy designation based on initial safety and activity data showing potential efficacy without intensive conditioning chemotherapy[6][4].

• FT522, a CD19-targeted CAR NK cell product incorporating Alloimmune Defense Receptor technology designed to reduce need for conditioning chemotherapy, showed persistence and anti-B cell activity through Day15 in relapsed/refractory B-cell lymphoma patients[4][9].

The company is actively expanding dose levels and indications while presenting translational data at major scientific meetings[9].